Paper1691908
Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy.
Prummel MF and 5 others. Arch Intern Med, 1990. Cited by 162 papers, by iCite.
Cite this record
ConductScience Library. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Papers, record 1691908. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1691908
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Graves Disease | Major topic |
| Thyroid Gland | Major topic |
| Adult | |
| Aged | |
| Antithyroid Agents | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Thyroid Function Tests |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 2331201 | Graves' ophthalmopathy. Is it really thyroid disease? | https://conductscience.org/library/papers/2331201 |
Source PubMed
Cited by59
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 162 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42871001 | Orbital decompression with intraorbital corticosteroid injection during the active phase of thyroid eye disease: outcomes in a real-world cohort. | Front Ophthalmol (Lausanne) | 2026 | https://conductscience.org/library/papers/42871001 | PubMed |
| 42741468 | How to manage thyroid eye disease: recent advances - a narrative review. | Drugs Context | 2026 | https://conductscience.org/library/papers/42741468 | PubMed |
| 42448986 | Head-to-Head Comparison of an IGF-1R Inhibitor Versus Intravenous Glucocorticoid for Active Thyroid Eye Disease: Design of a Randomized Clinical Trial. | Ophthalmol Ther | 2026 | https://conductscience.org/library/papers/42448986 | PubMed |
| 42275591 | The hidden impact of smoking in thyroid eye disease: a link between selenium deficiency, autoimmunity, and retinal microvasculature. | Arch Endocrinol Metab | 2026 | https://conductscience.org/library/papers/42275591 | PubMed |
| 41384130 | Assessment of disease activity in Graves' orbitopathy. | Front Ophthalmol (Lausanne) | 2025 | https://conductscience.org/library/papers/41384130 | PubMed |
| 41226056 | New-Onset Graves' Ophthalmopathy After Treatment with Pembrolizumab: A Case Report and a Review of the Literature. | Diagnostics (Basel) | 2025 | https://conductscience.org/library/papers/41226056 | PubMed |
| 40768183 | Process to radioactive iodine treatment for Graves' hyperthyroidism: condemned or absolved? | J Endocrinol Invest | 2025 | https://conductscience.org/library/papers/40768183 | PubMed |
| 39701285 | Management Aspects of Medical Therapy in Graves Disease. | Endocr Pract | 2025 | https://conductscience.org/library/papers/39701285 | PubMed |
| 39655097 | Otolaryngologist surgical preferences for orbital decompression in thyroid eye disease: A North American survey. | Laryngoscope Investig Otolaryngol | 2024 | https://conductscience.org/library/papers/39655097 | PubMed |
| 39443096 | Incidence of the postpartum diagnosis of thyroid eye disease in relation to thyroid function in Graves' disease. | Endocr J | 2025 | https://conductscience.org/library/papers/39443096 | PubMed |
| 38867959 | Efficacy of rituximab in treating steroid-resistant Graves' orbitopathy in active moderate-to-severe and sight-threatening forms: A retrospective observation from China. | Heliyon | 2024 | https://conductscience.org/library/papers/38867959 | PubMed |
| 37209204 | Effect of thyroid hormone status on complete blood cell count-derived inflammatory biomarkers in patients with moderate-to-severe Graves' ophthalmopathy. | Int Ophthalmol | 2023 | https://conductscience.org/library/papers/37209204 | PubMed |
| 37041348 | Sex-specific risk factors associated with graves' orbitopathy in Korean patients with newly diagnosed graves' disease. | Eye (Lond) | 2023 | https://conductscience.org/library/papers/37041348 | PubMed |
| 36627174 | Presentation of Graves' orbitopathy within European Group On Graves' Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III). | Br J Ophthalmol | 2024 | https://conductscience.org/library/papers/36627174 | PubMed |
| 36556950 | The Relationship between Obesity-Related Factors and Graves' Orbitopathy: A Pilot Study. | Medicina (Kaunas) | 2022 | https://conductscience.org/library/papers/36556950 | PubMed |
| 36272013 | Recent advances in graves ophthalmopathy medical therapy: a comprehensive literature review. | Int Ophthalmol | 2023 | https://conductscience.org/library/papers/36272013 | PubMed |
| 35791115 | Update on thyroid eye disease: Regional variations in prevalence, diagnosis, and management. | Indian J Ophthalmol | 2022 | https://conductscience.org/library/papers/35791115 | PubMed |
| 35604323 | Current concepts regarding Graves' orbitopathy. | J Intern Med | 2022 | https://conductscience.org/library/papers/35604323 | PubMed |
| 33926559 | Choroidal vascularity index in thyroid-associated ophthalmopathy: a cross-sectional study. | Eye Vis (Lond) | 2021 | https://conductscience.org/library/papers/33926559 | PubMed |
| 33374706 | Current Knowledge on Graves' Orbitopathy. | J Clin Med | 2020 | https://conductscience.org/library/papers/33374706 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/1691908
GET https://conductscience.org/api/papers/v1/1691908/cited_by?page=2